Business Context and Reporting Period
This Form 8-K filing by Henry Schein, Inc. (NASDAQ: HSIC) was filed on April 11, 2005, reporting events occurring on April 8, 2005. Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates four business groups: Dental, Medical, International, and Technology, serving over 475,000 customers in more than 125 countries.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, margin, debt, or liquidity figures for the current reporting period. The document references historical data in the "About Henry Schein" section, noting that the company's sales reached a record $4.1 billion in 2004.
Material Changes
The primary material change reported is a corporate governance update. On April 8, 2005, the Board of Directors authorized an increase in the number of directors from fourteen to fifteen. Paul Brons was appointed as a new director effective immediately to fill the vacancy. His term is set to expire at the annual meeting of stockholders on May 24, 2005.
Outlook, Management Commentary, and Risks
Management commentary focuses on the strategic value of the new board appointment. Stanley M. Bergman, Chairman and CEO, stated that Mr. Brons brings wide-ranging international business experience and pharmaceutical expertise, which will aid the company's international expansion and portfolio growth in pharmaceuticals, vaccines, and injectables. Mr. Brons expressed confidence in the company's corporate conduct standards and "Team Schein" culture. The filing does not disclose specific risks, contingencies, or unusual items beyond the standard corporate governance update.
Investor Verification Checklist
- Verify the effective date of Paul Brons' directorship and the expiration of his term at the May 24, 2005 annual meeting.
- Confirm the total number of directors on the board is now fifteen.
- Review Mr. Brons' background in pharmaceuticals and international business to assess alignment with Henry Schein's strategic goals.
- Note that this filing contains no new financial performance data; refer to the most recent 10-K or 10-Q for detailed financial metrics.